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Background: Randomized trials dealing with de-novo lesions have demonstrated that SeQuent Please (B.Braun, Melsungen, Germany) paclitaxel 
coated balloon angioplasty plus bare-metal stenting is non-inferior to paclitaxel eluting stenting in diabetic patients. Furthermore paclitaxel coated 
balloon plus endothelial progenitor cell capturing (EPC) stent implantation was superior to EPC stenting alone (PERfECT Stent Study). The efficacy 
and safety of the SeQuent Please drug-coated balloon (DCB) for treatment of de-novo coronary artery disease in a large-scale registry has not been 
addressed so far.
Methods and Results: The SeQuent Please World Wide registry is a multi-center (N=75), international, all comer, real world registry study 
including patients with DCB treatment. In 8 countries 2095 patients with 2348 lesions were included. Primary clinical endpoint was target 
lesion revascularization (TLR) at 9 months. There were 572 patients with de-novo lesions and DCB treatment. Diabetes mellitus was present in 
35.8%, hypertension in 81.3%, and hyperlipidemia in 65.9%. Lesion length was 16.4±7.1mm. Length of DCB was 19.1±5.3mm, inflation pressure 
11.4±3.2bar. Diameter of DCB was 2.6±0.4mm. Additional stenting was required in 29.3% of patients. Mean follow-up was 9.9 months. Patients 
with DCB alone versus DCB plus BMS for de-novo lesions had TLR 1.0% vs. 2.4% (p=0.31), TVR 1.0% vs. 3.6% (p=0.09), cardiac death 1.0% vs. 1.2% 
(p=0.86), myocardial infarction 0.7% vs. 0.0% (p=0.46) and MACE (composite of cardiac death, myocardial infarction due to target vessel, TLR) 
2.6% vs. 2.4% (p=0.91), respectively
Conclusions: In the large-scale, international, multi-center, prospective SeQuent Please World Wide Registry TLR, TVR and MACE were low in 
patients with paclitaxel coated balloon angioplasty for treatment of de-novo coronary artery disease. DCB treatment was predominantly performed 
in small vessels and required additional stenting in 29% with no difference in MACE and TLR and a trend towards a higher TVR rate with additional 
stenting compared to DCB alone.
